TO Title: a Novel Mrna Vaccine to Prevent Triple Negative Breast Cancer Idiq Title: Prevent Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers
Contract Overview
Contract Amount: $764,880 ($764.9K)
Contractor: University of Oklahoma
Awarding Agency: Department of Health and Human Services
Start Date: 2024-06-17
End Date: 2026-06-16
Contract Duration: 729 days
Daily Burn Rate: $1.0K/day
Official Description: TO TITLE: A NOVEL MRNA VACCINE TO PREVENT TRIPLE NEGATIVE BREAST CANCER IDIQ TITLE: PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS
Place of Performance
Location: Oklahoma, 73104
State: Oklahoma Government Spending